Figure 5.
Predicting the response to immune checkpoint blockade therapy and revealed diverse overall survival outcomes in the three immunophenotypes
(A) Prediction results of the response to anti-PD-L1 therapy. (B) Prediction results of the response to anti-CTAL-4 and anti-PD-1 therapy. (C) Different overall survival outcomes in the three immunophenotypes.